Skip to main content
CVE:EVE

Eve & Co Incorporated Competitors

C$0.28
-0.01 (-1.75 %)
(As of 05/18/2021 01:25 PM ET)
Add
Compare
Today's Range
C$0.27
C$0.29
50-Day Range
C$0.26
C$0.40
52-Week Range
C$0.25
C$1.30
Volume28,216 shs
Average Volume85,867 shs
Market CapitalizationC$8.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Eve & Co Incorporated (CVE:EVE) Vs. ASP, FLWR, RX, CPH, MDP, and VIR

Should you be buying EVE stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Eve & Co Incorporated, including Acerus Pharmaceuticals (ASP), The Flowr (FLWR), BioSyent (RX), Cipher Pharmaceuticals (CPH), Medexus Pharmaceuticals (MDP), and Viridium Pacific Group (VIR).

Eve & Co Incorporated (CVE:EVE) and Acerus Pharmaceuticals (TSE:ASP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Profitability

This table compares Eve & Co Incorporated and Acerus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eve & Co IncorporatedN/AN/AN/A
Acerus PharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares Eve & Co Incorporated and Acerus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eve & Co IncorporatedC$2.84 million2.84C$-9,154,266.00C($0.32)-0.88
Acerus PharmaceuticalsC$-5,030,000.00-15.28C$-59,965,932.00C($0.04)-1.28

Eve & Co Incorporated has higher revenue and earnings than Acerus Pharmaceuticals. Acerus Pharmaceuticals is trading at a lower price-to-earnings ratio than Eve & Co Incorporated, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Eve & Co Incorporated and Acerus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eve & Co Incorporated0000N/A
Acerus Pharmaceuticals0000N/A

Summary

Eve & Co Incorporated beats Acerus Pharmaceuticals on 4 of the 5 factors compared between the two stocks.

The Flowr (CVE:FLWR) and Eve & Co Incorporated (CVE:EVE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for The Flowr and Eve & Co Incorporated, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Flowr0000N/A
Eve & Co Incorporated0000N/A

The Flowr currently has a consensus price target of C$0.88, suggesting a potential upside of 268.06%. Given The Flowr's higher probable upside, research analysts clearly believe The Flowr is more favorable than Eve & Co Incorporated.

Profitability

This table compares The Flowr and Eve & Co Incorporated's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The FlowrN/AN/AN/A
Eve & Co IncorporatedN/AN/AN/A

Valuation & Earnings

This table compares The Flowr and Eve & Co Incorporated's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The FlowrC$7.51 million11.56C$-343,678,650.00C($0.95)-0.25
Eve & Co IncorporatedC$2.84 million2.84C$-9,154,266.00C($0.32)-0.88

Eve & Co Incorporated has lower revenue, but higher earnings than The Flowr. Eve & Co Incorporated is trading at a lower price-to-earnings ratio than The Flowr, indicating that it is currently the more affordable of the two stocks.

Summary

The Flowr beats Eve & Co Incorporated on 4 of the 6 factors compared between the two stocks.

Eve & Co Incorporated (CVE:EVE) and BioSyent (CVE:RX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for Eve & Co Incorporated and BioSyent, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eve & Co Incorporated0000N/A
BioSyent02002.00

BioSyent has a consensus target price of C$7.00, suggesting a potential downside of 6.91%. Given BioSyent's higher probable upside, analysts plainly believe BioSyent is more favorable than Eve & Co Incorporated.

Valuation and Earnings

This table compares Eve & Co Incorporated and BioSyent's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eve & Co IncorporatedC$2.84 million2.84C$-9,154,266.00C($0.32)-0.88
BioSyentC$22.33 million4.28C$3.68 millionC$0.2925.93

BioSyent has higher revenue and earnings than Eve & Co Incorporated. Eve & Co Incorporated is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eve & Co Incorporated and BioSyent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eve & Co IncorporatedN/AN/AN/A
BioSyentN/AN/AN/A

Summary

BioSyent beats Eve & Co Incorporated on 6 of the 6 factors compared between the two stocks.

Eve & Co Incorporated (CVE:EVE) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Eve & Co Incorporated and Cipher Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eve & Co Incorporated0000N/A
Cipher Pharmaceuticals00103.00

Earnings & Valuation

This table compares Eve & Co Incorporated and Cipher Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eve & Co IncorporatedC$2.84 million2.84C$-9,154,266.00C($0.32)-0.88
Cipher PharmaceuticalsC$21.61 million1.79C$5.42 millionC$0.207.11

Cipher Pharmaceuticals has higher revenue and earnings than Eve & Co Incorporated. Eve & Co Incorporated is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eve & Co Incorporated and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eve & Co IncorporatedN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/A

Summary

Cipher Pharmaceuticals beats Eve & Co Incorporated on 5 of the 6 factors compared between the two stocks.

Eve & Co Incorporated (CVE:EVE) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Valuation & Earnings

This table compares Eve & Co Incorporated and Medexus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eve & Co IncorporatedC$2.84 million2.84C$-9,154,266.00C($0.32)-0.88
Medexus PharmaceuticalsC$108.29 million1.25C$-34,573,801.00C($1.81)-3.91

Eve & Co Incorporated has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Eve & Co Incorporated, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eve & Co Incorporated and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eve & Co IncorporatedN/AN/AN/A
Medexus PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Eve & Co Incorporated and Medexus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eve & Co Incorporated0000N/A
Medexus Pharmaceuticals00203.00

Summary

Eve & Co Incorporated beats Medexus Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

Viridium Pacific Group (CVE:VIR) and Eve & Co Incorporated (CVE:EVE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Viridium Pacific Group and Eve & Co Incorporated's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridium Pacific GroupN/AN/AN/A
Eve & Co IncorporatedN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Viridium Pacific Group and Eve & Co Incorporated, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridium Pacific Group0000N/A
Eve & Co Incorporated0000N/A

Earnings & Valuation

This table compares Viridium Pacific Group and Eve & Co Incorporated's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridium Pacific GroupC$1.09 million34.46C$-12,637,824.00C($0.13)-2.97
Eve & Co IncorporatedC$2.84 million2.84C$-9,154,266.00C($0.32)-0.88

Eve & Co Incorporated has higher revenue and earnings than Viridium Pacific Group. Viridium Pacific Group is trading at a lower price-to-earnings ratio than Eve & Co Incorporated, indicating that it is currently the more affordable of the two stocks.

Summary

Eve & Co Incorporated beats Viridium Pacific Group on 3 of the 5 factors compared between the two stocks.


Eve & Co Incorporated Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05-10.0%C$76.88 millionC$-5,030,000.00-1.28Gap Up
FLWR
The Flowr
1.0$0.24-0.0%C$70.01 millionC$7.51 million-0.25
RX
BioSyent
0.8$7.52-0.8%C$64.81 millionC$22.33 million25.93
Cipher Pharmaceuticals logo
CPH
Cipher Pharmaceuticals
0.7$1.43-2.1%C$39.38 millionC$21.61 million7.11
MDP
Medexus Pharmaceuticals
0.6$7.09-0.1%C$38.66 millionC$108.29 million-3.91
VIR
Viridium Pacific Group
0.7$0.38-5.3%C$37.54 millionC$1.09 million-2.97Gap Up
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29-7.0%C$36.73 millionN/A-2.61Gap Down
IN
InMed Pharmaceuticals
0.6$4.19-1.7%C$33.73 millionN/A-2.40
NDVA
Indiva
1.3$0.39-5.1%C$27.54 millionC$7.92 million-3.05Gap Up
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.08-6.3%C$21.51 millionC$8.50 million-0.22
SUGR
SugarBud Craft Growers
0.7$0.05-0.0%C$11.81 millionC$66,906.00-0.03News Coverage
Gap Up
NU
NeutriSci International
0.5$0.17-3.0%C$8.65 millionC$74,572.00-11.79Gap Up
AQS
Aequus Pharmaceuticals
0.9$0.15-3.4%C$6.03 millionC$2.59 million-13.18
LBL
Lattice Biologics
0.5$0.04-0.0%C$4.67 millionC$2.24 million-2.22
THCX
(THCX.V)
0.6$5.30-6.2%C$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Up
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Up
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00Gap Up
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00Gap Up
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.